Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) obtained approval for the investigational new drug application for its SKB501 from China's National Medical Products Administration on Monday, a same-day bourse filing said.
SKB501 is intended to be used for the treatment of advanced solid tumors, a biopharmaceutical company said.